Expert Interviews

Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.

Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).

Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."

At the 2022 American Academy of Ophthalmology meeting, Dr Philip Dockery, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.

Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"

At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."

Dr Mark H. Blecher dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."

At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

David Hutton discusses the AAO 2022 talk, "Corneal Oedema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with presenter Dr Francis S. Mah.

David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

Prof. Martin Dirisamer speaks with Editor Caroline Richards about his ESCRS instructional course, "Mastering laser refractive surgery: Indications and outcomes."

Dr David Lubeck talks with Caroline Richards of Ophthalmology Times Europe about his ESCRS presentations, touching on surgical effects on corneal epithelium and the iTrack Global Registry for glaucoma.

Prof. Martin Dirisamer discusses his instructional course on common mistakes when performing DMEK and how to avoid them at ESCRS.

Assistant Prof. of ophthalmology Basak Bostanci discusses her ESCRS presentation, “Extended Range Of Vision In Unusual Cases” and how EDOF lens technology is evolving to include a wider pool of candidates.

Prof. Ioannis Pallikaris discusses his 2022 ESCRS presentation: "Peripheral Capsule Reconstruction And IOL Centration With The Fixoflex Ring".

Tunde Peto, MD, PhD, shares some ophthalmic initiatives she's excited about in light of EURETINA 2022.

Tunde Peto, MD, PhD, discussed two of her presentations at EURETINA 2022: "UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases" and "Retinal phenotyping of different variants of Alzheimer’s disease using ultra-widefield imaging."

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

Victor Gonzalez, MD, shares updates from the Phase 4 Paladin study regarding the safety and efficacy of fluocinolone in diabetic macular edema.

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.